SABS: SAB Biotherapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | 13G amendment | Perceptive Advisors LLC | 7.30% | SEC | |
| 2026-08-14 | 13G amendment | Caligan Partners LP | 8.80% | SEC | |
| 2026-08-14 | 13G amendment | Commodore Capital LP | 9.90% | SEC | |
| 2026-08-14 | 13G amendment | Vivo Opportunity Fund Holdings, L.P. | 9.99% | SEC | |
| 2026-08-14 | 13G amendment | Woodline Partners LP | 6.80% | SEC | |
| 2026-08-14 | 13G amendment | BALYASNY ASSET MANAGEMENT L.P. | 9.45% | SEC | |
| 2026-08-12 | New 13G stake | Adage Capital Management, L.P. | 8.38% | SEC | |
| 2026-08-10 | 13D amendment | RA Capital Management, L.P. | 9.90% | SEC |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.